

D

1

2

3

4


5

6




D J

J




D D




J

D






D

D



JJ




-
-
-
-

D

D



1

2

3


4

5

6

Revenue


Non-Ortho
Ortho



Group revenue up 15% excl. FX, 14% as reported


Operating Expenses

Non-Ortho
Ortho



Percentage of sales improved by 4 percentage points


Gross Profit Margin



Gross Margin improved by 2 percentage points

Net Profit Attributable to Equity Shareholder


Non-Ortho
Ortho



Net profit attributable to equity shareholder up by 33%




Sales and Marketing Expenses




-
-

Administrative Expenses






-
-

Research and Develop. Expenses



-
-





1

2

3


4

5

6

Revenue

Revenue by Geographic Areas




Highlights


-
- - D
 -
 - J
 -
 -
- -
- - D
 -



Revenue



2017 SuperPath™ and Evolution™



- D
- D



D



D

D




D

D




Revenue of Cardiovascular Business




Domestic Sales Growth by Products

Firehawk™ : 61% ↑ ; Firebird™ : 9% ↑



Performance of DES in Domestic Market



Highlights

- -
 -
 -
 -
 -
 -
 -
 -
 -
 -
 -
 -
 -
 -
- D
D



Promising Results of Target AC Clinical Trial


New Countries & Distributors Development

Highlights


- D
- D
-
-
-
- -
 -
-




Revenue



Extensive Product Pipeline



Sales Growth by Products




Highlights


-
-
-
-
- D
- J



Revenue




Sales Growth by Products



Pipeline -- Full range of solutions

JJ



D

D


Highlights

- - JJ
 - JJ
- -
 -
 -
- - JJ
 - JJ





D



J

D




1

2

3

4

5



Horizontal dashed lines for writing, aligned with the colored bars on the left.

1


2

3

4

5

6





[Redacted text]

[Redacted text]

[Redacted text]



[Redacted text]

[Redacted text]


[Redacted text]



[Redacted text]

[Redacted text]

[Redacted text]





[Redacted text]





-
-
-
-



1

2

3

4

5

6

(USD '000)	2017	2016	Flux %
Revenue	444,190	389,921	14.0%
Cost of sales	(125,793)	(118,243)	6.4%
Gross profit	318,397	271,678	17.2%
Other revenue & net gain/(loss)	(2,540)	20,677	-112.3%
Research and development costs	(58,150)	(51,897)	12.0%
Distribution costs	(137,766)	(128,464)	7.2%
Administrative expenses	(66,804)	(64,245)	4.0%
Other operating costs	(5,276)	(1,818)	190.2%
Operating Profit	47,861	45,931	4.2%
Finance costs	(13,489)	(16,704)	19.2%
Gain on disposal of subsidiaries	6,531		N/A
Share of losses of JV and associates	(10,535)	(3,941)	167.3%
Profit before taxation	30,368	25,286	20.1%
Income tax	(13,417)	(10,217)	31.3%
Net profit	16,951	15,069	12.5%
Profit attributable to equity shareholders	18,823	14,141	33.1%



